Table 3 DMARD use in the follow-up period from SSZ trial inclusion to review for follow-up of 61 juvenile idiopathic arthritis patients who participated in a placebo-controlled sulfasalazine trial13*
VariablePlacebo group n = 29Sulfasalazine group n = 32p value
Medication use in follow-up period
No. of DMARDS used in follow-up period, median (range)2 (0 to 5)1.5 (1 to 5)NS
No. (%) of patients with SSZ use24 (83)32 (100)0.02
    Duration of SSZ use in years, median (IQR)5.2 (2.1 to 8.0)2.5 (0.5 to 4.9)0.02
No. (%) of patients with MTX use16 (55)15 (47)NS
    Duration of MTX use in years, median (IQR)4.0 (3.0 to 5.8)3.0 (1.5 to 5.0)NS
No. (%) of patients with prednisone use3 (10)2 (6)NS
    Duration of prednisone use in years, median (IQR)2.0 (2.0 to 6.0)0.9 (0.3 to 1.5)NS
No. (%) of patients with intramuscular gold use3 (10)5 (16)NS
    Duration of intramuscular gold use in years, median (IQR)4.0 (1.5 to 7.0)1.5 (0.5 to 2.8)NS
No. (%) of patients with hydroxychloroquine use03 (9)
    Duration of hydroxychloroquine use in years, median (IQR)06.2 (0.1 to 6.5)
No. of patients with use of other DMARDs†11
Current medication use
No. (%) of patients with current DMARD use21 (72)17 (53)NS
No. of patients with current use of:
    SSZ monotherapy104
    SSZ in combination treatment4 MTX2 MTX
    MTX monotherapy68
    MTX in combination treatment4 SSZ, 1 prednisone2 SSZ, 1 HCQ
    Hydroxychloroquine01
    Antitumor necrosis factor01
  • *SSZ, sulfasalazine; HCQ, hydroxychloroquine; †other DMARDs included: in 1 PLAC patient: 9 months’ treatment with ciclosporin and an autologous bone marrow transplantation,27 respectively in 1 SSZ patient: 6 months of leflunomide treatment followed by recent introduction of anti-TNF-treatment.